{"id":4791,"date":"2026-04-30T08:02:04","date_gmt":"2026-04-30T08:02:04","guid":{"rendered":"https:\/\/bangkokpeptides.com\/?page_id=4791"},"modified":"2026-08-17T09:09:48","modified_gmt":"2026-08-17T09:09:48","slug":"retatrutide","status":"publish","type":"page","link":"https:\/\/bangkokpeptides.com\/th\/library\/retatrutide\/","title":{"rendered":"Compound Library &#8211; Retatrutide"},"content":{"rendered":"\n<!-- ============================================================\n BANGKOK PEPTIDES \u2014 COMPOUND LIBRARY\n \/library\/retatrutide\/\n \n Flagship editorial entry. Cream\/gold\/black aesthetic.\n Designed to function as both prestige content and conversion page.\n \n Paste the full block below into the WordPress page editor as a\n Custom HTML block. Then add the schema separately as a\n Custom HTML block at the bottom.\n============================================================ -->\n\n\n<style>\n.bp-cl * { box-sizing: border-box; }\n\n.bp-cl {\n background: #faf7ee;\n font-family: 'Inter', 'Helvetica Neue', Arial, sans-serif;\n color: #1a1a1a;\n line-height: 1.65;\n}\n\n.bp-cl-section {\n width: 100vw;\n margin-left: calc(50% - 50vw);\n padding: 0 1.5rem;\n}\n\n.bp-cl-inner {\n max-width: 1100px;\n margin: 0 auto;\n padding: 5rem 0;\n}\n\n.bp-cl-eyebrow {\n display: inline-flex;\n align-items: center;\n gap: 0.85rem;\n font-family: 'Barlow', 'Inter', sans-serif;\n font-size: 0.7rem;\n font-weight: 700;\n letter-spacing: 0.28em;\n text-transform: uppercase;\n color: #c7a33a;\n margin: 0 0 1.5rem 0;\n}\n\n.bp-cl-eyebrow::before {\n content: '';\n display: block;\n width: 40px;\n height: 1px;\n background: rgba(199,163,58,0.5);\n}\n\n\n\/* \u2500\u2500\u2500 HERO \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\n.bp-cl-hero {\n background: linear-gradient(180deg, #0a0805 0%, #14100a 100%);\n color: #faf7ee;\n position: relative;\n overflow: hidden;\n border-bottom: 1px solid rgba(199,163,58,0.4);\n}\n\n.bp-cl-hero::before {\n content: '';\n position: absolute;\n top: 0; left: 0; right: 0;\n height: 1px;\n background: linear-gradient(90deg, transparent 0%, rgba(199,163,58,0.6) 50%, transparent 100%);\n}\n\n.bp-cl-hero::after {\n content: '';\n position: absolute;\n inset: 0;\n background: radial-gradient(ellipse 60% 80% at 70% 50%, rgba(199,163,58,0.08) 0%, transparent 70%);\n pointer-events: none;\n}\n\n.bp-cl-hero-inner {\n max-width: 1100px;\n margin: 0 auto;\n padding: 6rem 1.5rem 5rem;\n position: relative;\n z-index: 2;\n}\n\n.bp-cl-hero-eyebrow {\n display: inline-flex;\n align-items: center;\n gap: 0.85rem;\n font-family: 'Barlow', 'Inter', sans-serif;\n font-size: 0.7rem;\n font-weight: 700;\n letter-spacing: 0.32em;\n text-transform: uppercase;\n color: #c7a33a;\n margin: 0 0 2rem 0;\n flex-wrap: wrap;\n}\n\n.bp-cl-hero-eyebrow span {\n position: relative;\n padding: 0 0.5rem;\n}\n\n.bp-cl-hero-eyebrow span:not(:last-child)::after {\n content: '\u00b7';\n position: absolute;\n right: -0.25rem;\n color: rgba(199,163,58,0.6);\n}\n\n.bp-cl-hero-eyebrow .bp-cl-trial-badge {\n background: rgba(199,163,58,0.12);\n border: 1px solid rgba(199,163,58,0.4);\n padding: 0.35rem 0.7rem;\n font-size: 0.65rem;\n letter-spacing: 0.2em;\n border-radius: 2px;\n}\n\n.bp-cl-hero h1 {\n font-size: clamp(3rem, 8vw, 6rem);\n font-weight: 800;\n letter-spacing: -0.04em;\n line-height: 0.95;\n margin: 0 0 1.5rem 0;\n color: #faf7ee;\n}\n\n.bp-cl-hero h1 em {\n color: #c7a33a;\n font-style: italic;\n font-weight: 300;\n display: block;\n font-size: 0.55em;\n letter-spacing: -0.02em;\n margin-top: 0.5rem;\n}\n\n.bp-cl-hero-lede {\n font-size: clamp(1.15rem, 1.6vw, 1.4rem);\n line-height: 1.55;\n color: rgba(245,234,208,0.85);\n max-width: 720px;\n margin: 0 0 3rem 0;\n font-weight: 300;\n}\n\n.bp-cl-hero-lede strong {\n color: #c7a33a;\n font-weight: 600;\n}\n\n\/* Compound spec strip *\/\n.bp-cl-spec-strip {\n display: grid;\n grid-template-columns: repeat(auto-fit, minmax(160px, 1fr));\n gap: 0;\n border-top: 1px solid rgba(199,163,58,0.25);\n border-bottom: 1px solid rgba(199,163,58,0.25);\n margin: 2.5rem 0 0 0;\n}\n\n.bp-cl-spec {\n padding: 1.5rem 1.25rem;\n border-right: 1px solid rgba(199,163,58,0.18);\n position: relative;\n}\n\n.bp-cl-spec:last-child { border-right: none; }\n\n.bp-cl-spec-label {\n display: block;\n font-size: 0.65rem;\n letter-spacing: 0.2em;\n text-transform: uppercase;\n color: rgba(199,163,58,0.7);\n font-weight: 700;\n margin-bottom: 0.5rem;\n}\n\n.bp-cl-spec-value {\n display: block;\n font-size: 1.15rem;\n font-weight: 600;\n color: #faf7ee;\n letter-spacing: -0.005em;\n line-height: 1.2;\n}\n\n.bp-cl-spec-value-sm {\n font-size: 0.92rem;\n color: rgba(245,234,208,0.85);\n font-weight: 500;\n}\n\n\n\/* \u2500\u2500\u2500 INTRODUCTION \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\n.bp-cl-intro {\n background: #faf7ee;\n padding: 6rem 1.5rem;\n}\n\n.bp-cl-intro-inner {\n max-width: 800px;\n margin: 0 auto;\n}\n\n.bp-cl-intro h2 {\n font-size: clamp(2rem, 4vw, 2.85rem);\n font-weight: 800;\n letter-spacing: -0.025em;\n line-height: 1.15;\n color: #0a0805;\n margin: 0 0 2rem 0;\n}\n\n.bp-cl-intro h2 em {\n color: #c7a33a;\n font-style: italic;\n font-weight: 400;\n}\n\n.bp-cl-intro p {\n font-size: 1.1rem;\n line-height: 1.75;\n color: #2a2a2a;\n margin: 0 0 1.5rem 0;\n}\n\n.bp-cl-intro p strong {\n color: #0a0805;\n font-weight: 600;\n}\n\n.bp-cl-intro p:first-of-type::first-letter {\n font-family: 'Barlow', 'Inter', sans-serif;\n font-size: 5rem;\n font-weight: 800;\n color: #c7a33a;\n float: left;\n line-height: 0.85;\n margin: 0.3rem 0.75rem 0 0;\n font-style: italic;\n}\n\n\n\/* \u2500\u2500\u2500 MECHANISM (THE TRIPLE) \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\n.bp-cl-mechanism {\n background: #fff;\n padding: 6rem 1.5rem;\n border-top: 1px solid rgba(199,163,58,0.2);\n border-bottom: 1px solid rgba(199,163,58,0.2);\n}\n\n.bp-cl-mechanism-inner {\n max-width: 1100px;\n margin: 0 auto;\n}\n\n.bp-cl-mechanism-header {\n text-align: center;\n margin-bottom: 4rem;\n}\n\n.bp-cl-mechanism-header h2 {\n font-size: clamp(2rem, 4vw, 2.85rem);\n font-weight: 800;\n letter-spacing: -0.025em;\n line-height: 1.15;\n color: #0a0805;\n margin: 0 0 1.25rem 0;\n}\n\n.bp-cl-mechanism-header h2 em {\n color: #c7a33a;\n font-style: italic;\n font-weight: 400;\n}\n\n.bp-cl-mechanism-header p {\n font-size: 1.05rem;\n line-height: 1.65;\n color: #555;\n max-width: 680px;\n margin: 0 auto;\n}\n\n.bp-cl-receptor-grid {\n display: grid;\n grid-template-columns: repeat(3, 1fr);\n gap: 1.5rem;\n margin-bottom: 3rem;\n}\n\n.bp-cl-receptor {\n background: #faf7ee;\n border: 1px solid rgba(199,163,58,0.25);\n padding: 2.5rem 2rem;\n position: relative;\n transition: all 0.3s ease;\n}\n\n.bp-cl-receptor:hover {\n border-color: #c7a33a;\n transform: translateY(-3px);\n box-shadow: 0 12px 32px rgba(199,163,58,0.12);\n}\n\n.bp-cl-receptor-num {\n position: absolute;\n top: 1.5rem;\n right: 2rem;\n font-family: 'Barlow', 'Inter', sans-serif;\n font-size: 0.75rem;\n font-weight: 700;\n letter-spacing: 0.2em;\n color: rgba(199,163,58,0.6);\n}\n\n.bp-cl-receptor-symbol {\n display: inline-flex;\n align-items: center;\n justify-content: center;\n width: 56px;\n height: 56px;\n background: #0a0805;\n border: 1.5px solid #c7a33a;\n border-radius: 50%;\n margin-bottom: 1.5rem;\n font-family: 'Barlow', 'Inter', sans-serif;\n font-size: 1rem;\n font-weight: 700;\n letter-spacing: -0.02em;\n color: #c7a33a;\n}\n\n.bp-cl-receptor h3 {\n font-size: 1.35rem;\n font-weight: 700;\n letter-spacing: -0.01em;\n line-height: 1.2;\n color: #0a0805;\n margin: 0 0 0.75rem 0;\n}\n\n.bp-cl-receptor-shared {\n display: inline-block;\n font-size: 0.7rem;\n letter-spacing: 0.15em;\n text-transform: uppercase;\n color: #c7a33a;\n font-weight: 600;\n margin-bottom: 1rem;\n}\n\n.bp-cl-receptor p {\n font-size: 0.95rem;\n line-height: 1.6;\n color: #444;\n margin: 0;\n}\n\n\/* The differentiator callout *\/\n.bp-cl-differentiator {\n background: #0a0805;\n border: 1px solid rgba(199,163,58,0.4);\n padding: 3rem 2.5rem;\n text-align: center;\n position: relative;\n}\n\n.bp-cl-differentiator::before,\n.bp-cl-differentiator::after {\n content: '';\n position: absolute;\n width: 30px;\n height: 30px;\n border: 1px solid #c7a33a;\n}\n\n.bp-cl-differentiator::before {\n top: 1rem;\n left: 1rem;\n border-right: none;\n border-bottom: none;\n}\n\n.bp-cl-differentiator::after {\n bottom: 1rem;\n right: 1rem;\n border-left: none;\n border-top: none;\n}\n\n.bp-cl-differentiator-eyebrow {\n font-family: 'Barlow', 'Inter', sans-serif;\n font-size: 0.7rem;\n font-weight: 700;\n letter-spacing: 0.28em;\n text-transform: uppercase;\n color: #c7a33a;\n margin-bottom: 1.25rem;\n display: block;\n}\n\n.bp-cl-differentiator h3 {\n font-size: clamp(1.35rem, 2.5vw, 1.85rem);\n font-weight: 700;\n letter-spacing: -0.015em;\n line-height: 1.3;\n color: #faf7ee;\n margin: 0 0 1rem 0;\n max-width: 720px;\n margin-left: auto;\n margin-right: auto;\n}\n\n.bp-cl-differentiator h3 em {\n color: #c7a33a;\n font-style: italic;\n font-weight: 400;\n}\n\n.bp-cl-differentiator p {\n font-size: 1rem;\n line-height: 1.7;\n color: rgba(245,234,208,0.85);\n margin: 0 auto;\n max-width: 680px;\n}\n\n\n\/* \u2500\u2500\u2500 PHASE 2 DATA \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\n.bp-cl-data {\n background: #faf7ee;\n padding: 6rem 1.5rem;\n}\n\n.bp-cl-data-inner {\n max-width: 1100px;\n margin: 0 auto;\n}\n\n.bp-cl-data-header {\n display: grid;\n grid-template-columns: 1fr 1fr;\n gap: 4rem;\n align-items: end;\n margin-bottom: 4rem;\n}\n\n.bp-cl-data-header h2 {\n font-size: clamp(2rem, 4vw, 2.85rem);\n font-weight: 800;\n letter-spacing: -0.025em;\n line-height: 1.1;\n color: #0a0805;\n margin: 0;\n}\n\n.bp-cl-data-header h2 em {\n color: #c7a33a;\n font-style: italic;\n font-weight: 400;\n}\n\n.bp-cl-data-header-meta {\n font-size: 0.95rem;\n line-height: 1.65;\n color: #555;\n}\n\n.bp-cl-data-header-meta strong {\n color: #0a0805;\n font-weight: 600;\n}\n\n\/* The hero pull quote *\/\n.bp-cl-pullquote {\n background: linear-gradient(180deg, #0a0805 0%, #14100a 100%);\n color: #faf7ee;\n padding: 5rem 3rem;\n text-align: center;\n margin-bottom: 4rem;\n position: relative;\n border: 1px solid rgba(199,163,58,0.4);\n}\n\n.bp-cl-pullquote::before {\n content: '\"';\n position: absolute;\n top: 1rem;\n left: 2rem;\n font-family: 'Barlow', Georgia, serif;\n font-size: 6rem;\n color: rgba(199,163,58,0.25);\n line-height: 1;\n font-weight: 800;\n}\n\n.bp-cl-pullquote-stat {\n font-size: clamp(3.5rem, 8vw, 6rem);\n font-weight: 800;\n letter-spacing: -0.04em;\n line-height: 1;\n color: #c7a33a;\n margin: 0 0 1rem 0;\n font-family: 'Barlow', 'Inter', sans-serif;\n}\n\n.bp-cl-pullquote-stat em {\n font-style: italic;\n font-weight: 400;\n font-size: 0.5em;\n color: rgba(245,234,208,0.65);\n display: block;\n margin-top: 0.5rem;\n}\n\n.bp-cl-pullquote-headline {\n font-size: clamp(1.25rem, 2.2vw, 1.65rem);\n font-weight: 600;\n line-height: 1.4;\n color: #faf7ee;\n margin: 0 auto 1.5rem auto;\n max-width: 720px;\n letter-spacing: -0.01em;\n}\n\n.bp-cl-pullquote-citation {\n font-size: 0.85rem;\n letter-spacing: 0.15em;\n text-transform: uppercase;\n color: rgba(199,163,58,0.85);\n font-weight: 600;\n margin: 0;\n}\n\n\/* Dose-response table *\/\n.bp-cl-dose-table {\n background: #fff;\n border: 1px solid rgba(199,163,58,0.25);\n padding: 0;\n overflow: hidden;\n margin-bottom: 3rem;\n}\n\n.bp-cl-dose-table-header {\n background: #0a0805;\n color: #faf7ee;\n padding: 1.5rem 2rem;\n display: flex;\n justify-content: space-between;\n align-items: center;\n flex-wrap: wrap;\n gap: 1rem;\n border-bottom: 1px solid rgba(199,163,58,0.4);\n}\n\n.bp-cl-dose-table-title {\n font-family: 'Barlow', 'Inter', sans-serif;\n font-size: 0.85rem;\n font-weight: 700;\n letter-spacing: 0.18em;\n text-transform: uppercase;\n color: #c7a33a;\n margin: 0;\n}\n\n.bp-cl-dose-table-meta {\n font-size: 0.8rem;\n color: rgba(245,234,208,0.6);\n letter-spacing: 0.05em;\n}\n\n.bp-cl-dose-grid {\n display: grid;\n grid-template-columns: repeat(5, 1fr);\n}\n\n.bp-cl-dose-row {\n display: contents;\n}\n\n.bp-cl-dose-row > div {\n padding: 1.25rem 1.5rem;\n border-right: 1px solid rgba(199,163,58,0.15);\n border-bottom: 1px solid rgba(199,163,58,0.15);\n}\n\n.bp-cl-dose-row > div:last-child { border-right: none; }\n\n.bp-cl-dose-row.is-header > div {\n background: #faf7ee;\n font-size: 0.7rem;\n letter-spacing: 0.18em;\n text-transform: uppercase;\n color: #c7a33a;\n font-weight: 700;\n}\n\n.bp-cl-dose-row.is-highlight > div {\n background: rgba(199,163,58,0.08);\n font-weight: 600;\n}\n\n.bp-cl-dose-row > div .num {\n font-size: 1.15rem;\n font-weight: 700;\n color: #0a0805;\n font-family: 'Barlow', 'Inter', sans-serif;\n letter-spacing: -0.01em;\n}\n\n.bp-cl-dose-row > div .sub {\n font-size: 0.8rem;\n color: #666;\n display: block;\n margin-top: 0.2rem;\n}\n\n\n\/* \u2500\u2500\u2500 COMPARISON \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\n.bp-cl-compare {\n background: #fff;\n padding: 6rem 1.5rem;\n border-top: 1px solid rgba(199,163,58,0.2);\n}\n\n.bp-cl-compare-inner {\n max-width: 1100px;\n margin: 0 auto;\n}\n\n.bp-cl-compare-header {\n text-align: center;\n margin-bottom: 4rem;\n}\n\n.bp-cl-compare-header h2 {\n font-size: clamp(2rem, 4vw, 2.85rem);\n font-weight: 800;\n letter-spacing: -0.025em;\n line-height: 1.15;\n color: #0a0805;\n margin: 0 0 1.25rem 0;\n}\n\n.bp-cl-compare-header h2 em {\n color: #c7a33a;\n font-style: italic;\n font-weight: 400;\n}\n\n.bp-cl-compare-header p {\n font-size: 1.05rem;\n line-height: 1.65;\n color: #555;\n max-width: 680px;\n margin: 0 auto;\n}\n\n.bp-cl-compare-grid {\n display: grid;\n grid-template-columns: repeat(3, 1fr);\n gap: 1px;\n background: rgba(199,163,58,0.25);\n border: 1px solid rgba(199,163,58,0.25);\n}\n\n.bp-cl-compare-col {\n background: #faf7ee;\n padding: 2.5rem 2rem;\n position: relative;\n}\n\n.bp-cl-compare-col.is-featured {\n background: #0a0805;\n color: #faf7ee;\n}\n\n.bp-cl-compare-col.is-featured .bp-cl-compare-name {\n color: #c7a33a;\n}\n\n.bp-cl-compare-col.is-featured .bp-cl-compare-detail-label {\n color: rgba(199,163,58,0.7);\n}\n\n.bp-cl-compare-col.is-featured .bp-cl-compare-detail-value {\n color: #faf7ee;\n}\n\n.bp-cl-compare-col.is-featured .bp-cl-compare-detail {\n border-color: rgba(199,163,58,0.2);\n}\n\n.bp-cl-compare-tier {\n font-family: 'Barlow', 'Inter', sans-serif;\n font-size: 0.65rem;\n font-weight: 700;\n letter-spacing: 0.22em;\n text-transform: uppercase;\n color: #c7a33a;\n margin-bottom: 0.75rem;\n display: block;\n}\n\n.bp-cl-compare-name {\n font-size: 1.6rem;\n font-weight: 800;\n letter-spacing: -0.02em;\n color: #0a0805;\n margin: 0 0 0.5rem 0;\n line-height: 1.1;\n}\n\n.bp-cl-compare-receptor {\n font-size: 0.85rem;\n letter-spacing: 0.12em;\n text-transform: uppercase;\n color: #555;\n margin-bottom: 2rem;\n display: block;\n font-weight: 500;\n}\n\n.bp-cl-compare-col.is-featured .bp-cl-compare-receptor {\n color: rgba(245,234,208,0.7);\n}\n\n.bp-cl-compare-detail {\n padding: 1rem 0;\n border-bottom: 1px solid rgba(199,163,58,0.18);\n}\n\n.bp-cl-compare-detail:last-child { border-bottom: none; }\n\n.bp-cl-compare-detail-label {\n display: block;\n font-size: 0.68rem;\n letter-spacing: 0.18em;\n text-transform: uppercase;\n color: #888;\n font-weight: 600;\n margin-bottom: 0.4rem;\n}\n\n.bp-cl-compare-detail-value {\n font-size: 1rem;\n font-weight: 600;\n color: #0a0805;\n line-height: 1.3;\n}\n\n.bp-cl-compare-detail-value .em-num {\n font-size: 1.5rem;\n font-weight: 800;\n letter-spacing: -0.02em;\n color: #c7a33a;\n display: block;\n margin-bottom: 0.15rem;\n font-family: 'Barlow', 'Inter', sans-serif;\n}\n\n\n\/* \u2500\u2500\u2500 LITERATURE \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\n.bp-cl-lit {\n background: #faf7ee;\n padding: 6rem 1.5rem;\n}\n\n.bp-cl-lit-inner {\n max-width: 900px;\n margin: 0 auto;\n}\n\n.bp-cl-lit h2 {\n font-size: clamp(2rem, 4vw, 2.85rem);\n font-weight: 800;\n letter-spacing: -0.025em;\n line-height: 1.15;\n color: #0a0805;\n margin: 0 0 1.5rem 0;\n}\n\n.bp-cl-lit h2 em {\n color: #c7a33a;\n font-style: italic;\n font-weight: 400;\n}\n\n.bp-cl-lit-intro {\n font-size: 1.05rem;\n line-height: 1.7;\n color: #555;\n margin: 0 0 3.5rem 0;\n max-width: 680px;\n}\n\n.bp-cl-citation {\n display: grid;\n grid-template-columns: 60px 1fr;\n gap: 1.5rem;\n padding: 2rem 0;\n border-bottom: 1px solid rgba(199,163,58,0.2);\n align-items: start;\n}\n\n.bp-cl-citation:last-child { border-bottom: none; }\n\n.bp-cl-citation-num {\n font-family: 'Barlow', 'Inter', sans-serif;\n font-size: 1.5rem;\n font-weight: 700;\n color: #c7a33a;\n letter-spacing: -0.02em;\n font-style: italic;\n}\n\n.bp-cl-citation-content {\n display: flex;\n flex-direction: column;\n gap: 0.5rem;\n}\n\n.bp-cl-citation-meta {\n font-family: 'Barlow', 'Inter', sans-serif;\n font-size: 0.7rem;\n letter-spacing: 0.18em;\n text-transform: uppercase;\n color: #c7a33a;\n font-weight: 700;\n}\n\n.bp-cl-citation-title {\n font-size: 1.05rem;\n font-weight: 600;\n color: #0a0805;\n line-height: 1.4;\n margin: 0;\n}\n\n.bp-cl-citation-authors {\n font-size: 0.92rem;\n color: #555;\n font-style: italic;\n margin: 0;\n}\n\n.bp-cl-citation-journal {\n font-size: 0.9rem;\n color: #444;\n margin: 0;\n}\n\n.bp-cl-citation-journal strong {\n color: #0a0805;\n font-weight: 600;\n}\n\n\n\/* \u2500\u2500\u2500 PRODUCT TRANSITION (THE BUY MOMENT) \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\n.bp-cl-buy {\n background: linear-gradient(180deg, #0a0805 0%, #14100a 100%);\n color: #faf7ee;\n padding: 6rem 1.5rem;\n position: relative;\n border-top: 1px solid rgba(199,163,58,0.4);\n overflow: hidden;\n}\n\n.bp-cl-buy::before {\n content: '';\n position: absolute;\n inset: 0;\n background: radial-gradient(ellipse 80% 60% at 50% 100%, rgba(199,163,58,0.1) 0%, transparent 70%);\n pointer-events: none;\n}\n\n.bp-cl-buy-inner {\n max-width: 1100px;\n margin: 0 auto;\n position: relative;\n z-index: 2;\n display: grid;\n grid-template-columns: 1.3fr 1fr;\n gap: 5rem;\n align-items: center;\n}\n\n.bp-cl-buy-content {\n position: relative;\n}\n\n.bp-cl-buy-eyebrow {\n display: inline-flex;\n align-items: center;\n gap: 0.85rem;\n font-family: 'Barlow', 'Inter', sans-serif;\n font-size: 0.7rem;\n font-weight: 700;\n letter-spacing: 0.28em;\n text-transform: uppercase;\n color: #c7a33a;\n margin: 0 0 1.5rem 0;\n}\n\n.bp-cl-buy-eyebrow::before {\n content: '';\n display: block;\n width: 40px;\n height: 1px;\n background: rgba(199,163,58,0.5);\n}\n\n.bp-cl-buy h2 {\n font-size: clamp(2rem, 4.5vw, 3.25rem);\n font-weight: 800;\n letter-spacing: -0.03em;\n line-height: 1.05;\n color: #faf7ee;\n margin: 0 0 1.5rem 0;\n}\n\n.bp-cl-buy h2 em {\n color: #c7a33a;\n font-style: italic;\n font-weight: 400;\n}\n\n.bp-cl-buy-lede {\n font-size: 1.05rem;\n line-height: 1.7;\n color: rgba(245,234,208,0.85);\n margin: 0 0 2.5rem 0;\n max-width: 540px;\n}\n\n.bp-cl-buy-specs {\n display: grid;\n grid-template-columns: repeat(3, 1fr);\n gap: 0;\n border-top: 1px solid rgba(199,163,58,0.25);\n border-bottom: 1px solid rgba(199,163,58,0.25);\n margin-bottom: 2.5rem;\n}\n\n.bp-cl-buy-spec {\n padding: 1.25rem 1rem;\n border-right: 1px solid rgba(199,163,58,0.18);\n}\n\n.bp-cl-buy-spec:last-child { border-right: none; }\n\n.bp-cl-buy-spec-label {\n display: block;\n font-size: 0.65rem;\n letter-spacing: 0.2em;\n text-transform: uppercase;\n color: rgba(199,163,58,0.7);\n font-weight: 700;\n margin-bottom: 0.4rem;\n}\n\n.bp-cl-buy-spec-value {\n display: block;\n font-size: 1.05rem;\n font-weight: 600;\n color: #faf7ee;\n letter-spacing: -0.005em;\n}\n\n.bp-cl-buy-cta-row {\n display: flex;\n gap: 1rem;\n align-items: center;\n flex-wrap: wrap;\n}\n\n.bp-cl-buy-cta {\n display: inline-flex;\n align-items: center;\n gap: 0.75rem;\n background: #c7a33a;\n color: #0a0805;\n padding: 1.15rem 2.5rem;\n text-decoration: none;\n font-weight: 700;\n font-size: 0.85rem;\n letter-spacing: 0.18em;\n text-transform: uppercase;\n border: 1.5px solid #c7a33a;\n transition: all 0.25s ease;\n}\n\n.bp-cl-buy-cta:hover {\n background: transparent;\n color: #c7a33a;\n transform: translateX(4px);\n}\n\n.bp-cl-buy-cta-secondary {\n display: inline-flex;\n align-items: center;\n gap: 0.5rem;\n color: #c7a33a;\n text-decoration: none;\n font-weight: 600;\n font-size: 0.78rem;\n letter-spacing: 0.12em;\n text-transform: uppercase;\n border-bottom: 1px solid #c7a33a;\n padding-bottom: 2px;\n transition: all 0.2s ease;\n}\n\n.bp-cl-buy-cta-secondary:hover {\n color: #faf7ee;\n border-color: #faf7ee;\n}\n\n.bp-cl-buy-price {\n font-family: 'Barlow', 'Inter', sans-serif;\n font-size: 0.85rem;\n letter-spacing: 0.15em;\n color: rgba(245,234,208,0.7);\n margin: 1.5rem 0 0 0;\n font-weight: 500;\n text-transform: uppercase;\n}\n\n.bp-cl-buy-price strong {\n color: #c7a33a;\n font-size: 1.5rem;\n font-weight: 700;\n letter-spacing: -0.01em;\n display: inline-block;\n margin-right: 0.5rem;\n text-transform: none;\n font-family: 'Barlow', sans-serif;\n}\n\n\/* The product visual *\/\n.bp-cl-buy-visual {\n position: relative;\n aspect-ratio: 1 \/ 1.1;\n display: flex;\n align-items: center;\n justify-content: center;\n}\n\n.bp-cl-buy-visual::before {\n content: '';\n position: absolute;\n inset: 10%;\n border: 1px solid rgba(199,163,58,0.3);\n border-radius: 50%;\n}\n\n.bp-cl-buy-visual::after {\n content: '';\n position: absolute;\n inset: 20%;\n border: 1px solid rgba(199,163,58,0.2);\n border-radius: 50%;\n}\n\n.bp-cl-buy-visual img {\n position: relative;\n z-index: 2;\n max-width: 80%;\n height: auto;\n filter: drop-shadow(0 20px 40px rgba(199,163,58,0.25));\n}\n\n\n\/* \u2500\u2500\u2500 RESPONSIVE \u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500\u2500 *\/\n@media (max-width: 900px) {\n .bp-cl-hero-inner { padding: 4rem 1.25rem 3rem; }\n .bp-cl-intro,\n .bp-cl-mechanism,\n .bp-cl-data,\n .bp-cl-compare,\n .bp-cl-lit,\n .bp-cl-buy { padding: 4rem 1.25rem; }\n \n .bp-cl-receptor-grid { grid-template-columns: 1fr; gap: 1rem; }\n .bp-cl-data-header { grid-template-columns: 1fr; gap: 1.5rem; }\n .bp-cl-compare-grid { grid-template-columns: 1fr; }\n .bp-cl-buy-inner { grid-template-columns: 1fr; gap: 3rem; }\n \n .bp-cl-dose-grid { grid-template-columns: repeat(3, 1fr); }\n .bp-cl-dose-grid > .bp-cl-dose-row > div:nth-child(4),\n .bp-cl-dose-grid > .bp-cl-dose-row > div:nth-child(5) { display: none; }\n \n .bp-cl-buy-specs { grid-template-columns: 1fr 1fr; }\n .bp-cl-buy-spec:nth-child(2) { border-right: none; }\n .bp-cl-buy-spec:nth-child(3) { \n grid-column: 1 \/ -1; \n border-top: 1px solid rgba(199,163,58,0.18); \n }\n}\n\n@media (max-width: 600px) {\n .bp-cl-hero-inner { padding: 3rem 1rem 2.5rem; }\n .bp-cl-spec-strip { grid-template-columns: 1fr 1fr; }\n .bp-cl-spec:nth-child(2) { border-right: none; }\n .bp-cl-spec:nth-child(3),\n .bp-cl-spec:nth-child(4) { \n border-top: 1px solid rgba(199,163,58,0.18); \n }\n \n .bp-cl-pullquote { padding: 3rem 1.5rem; }\n .bp-cl-differentiator { padding: 2rem 1.5rem; }\n .bp-cl-citation { grid-template-columns: 40px 1fr; gap: 1rem; }\n .bp-cl-buy-specs { grid-template-columns: 1fr; }\n .bp-cl-buy-spec { border-right: none; border-bottom: 1px solid rgba(199,163,58,0.18); }\n .bp-cl-buy-spec:last-child { border-bottom: none; }\n}\n<\/style>\n\n\n<div class=\"bp-cl\">\n\n <!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n HERO\n \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n <section class=\"bp-cl-hero\">\n <div class=\"bp-cl-hero-inner\">\n \n <div class=\"bp-cl-hero-eyebrow\">\n <span>Compound Library<\/span>\n <span>Volume I<\/span>\n <span class=\"bp-cl-trial-badge\">Phase 3 \u2014 TRIUMPH<\/span>\n <\/div>\n \n <h1>\n Retatrutide\n <em>Triple-receptor agonist<\/em>\n <\/h1>\n \n <p class=\"bp-cl-hero-lede\">\n The first peptide to engage <strong>GLP-1, GIP, and glucagon receptors<\/strong> simultaneously \u2014 and the most extensively studied compound in current metabolic research literature.\n <\/p>\n \n <div class=\"bp-cl-spec-strip\">\n <div class=\"bp-cl-spec\">\n <span class=\"bp-cl-spec-label\">CAS Number<\/span>\n <span class=\"bp-cl-spec-value\">2381089-83-2<\/span>\n <\/div>\n <div class=\"bp-cl-spec\">\n <span class=\"bp-cl-spec-label\">Class<\/span>\n <span class=\"bp-cl-spec-value\">Triple Agonist<\/span>\n <span class=\"bp-cl-spec-value-sm\">GLP-1 \/ GIP \/ GCGR<\/span>\n <\/div>\n <div class=\"bp-cl-spec\">\n <span class=\"bp-cl-spec-label\">Developer<\/span>\n <span class=\"bp-cl-spec-value\">Eli Lilly<\/span>\n <span class=\"bp-cl-spec-value-sm\">LY3437943<\/span>\n <\/div>\n <div class=\"bp-cl-spec\">\n <span class=\"bp-cl-spec-label\">First Published<\/span>\n <span class=\"bp-cl-spec-value\">NEJM 2023<\/span>\n <span class=\"bp-cl-spec-value-sm\">Jastreboff et al.<\/span>\n <\/div>\n <\/div>\n \n <\/div>\n <\/section>\n\n\n <!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n INTRODUCTION\n \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n <section class=\"bp-cl-intro\">\n <div class=\"bp-cl-intro-inner\">\n \n <div class=\"bp-cl-eyebrow\">Introduction<\/div>\n \n <h2>A new generation of <em>metabolic peptide.<\/em><\/h2>\n \n <p>Retatrutide is a synthetic 39-amino-acid peptide developed by Eli Lilly under the development code LY3437943. It was designed from the ground up as a single molecule capable of simultaneously activating three distinct receptors involved in energy homeostasis \u2014 GLP-1, GIP, and glucagon (GCGR) \u2014 making it the first true triple-receptor agonist to enter advanced clinical development.<\/p>\n \n <p>What makes retatrutide pharmacologically distinct from its predecessors is the deliberate inclusion of <strong>glucagon receptor activity<\/strong>. Earlier generations \u2014 semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP) \u2014 focused on suppressing appetite and improving insulin signalling. Retatrutide adds a third pathway that drives energy expenditure directly through the liver and brown adipose tissue, fundamentally changing the mechanism profile.<\/p>\n \n <p>The result, in published Phase 2 data, is the largest body weight reduction ever recorded in a mainstream obesity trial \u2014 a finding that has reshaped how the metabolic research community thinks about pharmacological weight management. Retatrutide is now in Phase 3 clinical trials (the TRIUMPH program), with FDA approval anticipated in the 2026\u20132027 window.<\/p>\n \n <\/div>\n <\/section>\n\n\n <!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n MECHANISM \u2014 THE TRIPLE\n \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n <section class=\"bp-cl-mechanism\">\n <div class=\"bp-cl-mechanism-inner\">\n \n <div class=\"bp-cl-mechanism-header\">\n <div class=\"bp-cl-eyebrow\" style=\"justify-content: center;\">Mechanism<\/div>\n <h2>Three receptors, <em>one molecule.<\/em><\/h2>\n <p>Retatrutide&#8217;s pharmacology is defined by simultaneous engagement across three distinct G-protein-coupled receptors. Each contributes a different metabolic effect \u2014 and the combination is what produces the compound&#8217;s research signal.<\/p>\n <\/div>\n \n <div class=\"bp-cl-receptor-grid\">\n \n <div class=\"bp-cl-receptor\">\n <span class=\"bp-cl-receptor-num\">I.<\/span>\n <span class=\"bp-cl-receptor-symbol\">GLP-1<\/span>\n <h3>GLP-1 Receptor<\/h3>\n <span class=\"bp-cl-receptor-shared\">Shared with Semaglutide \u00b7 Tirzepatide<\/span>\n <p>Glucagon-like peptide-1 receptor activation. Suppresses appetite via central nervous system pathways, slows gastric emptying, and improves glucose-dependent insulin secretion. The foundation pathway shared by all modern incretin therapies.<\/p>\n <\/div>\n \n <div class=\"bp-cl-receptor\">\n <span class=\"bp-cl-receptor-num\">II.<\/span>\n <span class=\"bp-cl-receptor-symbol\">GIP<\/span>\n <h3>GIP Receptor<\/h3>\n <span class=\"bp-cl-receptor-shared\">Shared with Tirzepatide<\/span>\n <p>Glucose-dependent insulinotropic polypeptide receptor. Adds a second incretin pathway with effects on insulin sensitivity, lipid metabolism, and adipose tissue function. The addition that distinguished tirzepatide from semaglutide.<\/p>\n <\/div>\n \n <div class=\"bp-cl-receptor\">\n <span class=\"bp-cl-receptor-num\">III.<\/span>\n <span class=\"bp-cl-receptor-symbol\">GCGR<\/span>\n <h3>Glucagon Receptor<\/h3>\n <span class=\"bp-cl-receptor-shared\">Unique to Retatrutide<\/span>\n <p>Glucagon receptor activation. Directly increases energy expenditure via hepatic glucose output and brown adipose tissue thermogenesis. The third pathway that defines retatrutide as a true triple agonist \u2014 and drives its distinct metabolic signal.<\/p>\n <\/div>\n \n <\/div>\n \n <div class=\"bp-cl-differentiator\">\n <span class=\"bp-cl-differentiator-eyebrow\">The Differentiator<\/span>\n <h3>The glucagon pathway is what separates retatrutide from <em>everything before it.<\/em><\/h3>\n <p>While GLP-1 and GIP suppress intake, glucagon receptor agonism increases energy output. The combination produces both sides of the energy equation simultaneously \u2014 and is associated with the compound&#8217;s striking effect on hepatic fat content, with an 81.4% mean reduction in liver fat reported in the NAFLD sub-study (Sanyal et al., Nature Medicine 2024).<\/p>\n <\/div>\n \n <\/div>\n <\/section>\n\n\n <!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n PHASE 2 DATA\n \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n <section class=\"bp-cl-data\">\n <div class=\"bp-cl-data-inner\">\n \n <div class=\"bp-cl-data-header\">\n <div>\n <div class=\"bp-cl-eyebrow\">Trial Data<\/div>\n <h2>The Phase 2 <em>signal.<\/em><\/h2>\n <\/div>\n <div class=\"bp-cl-data-header-meta\">\n <p><strong>Jastreboff et al., NEJM 2023.<\/strong> Randomised, double-blind, placebo-controlled Phase 2 trial in 338 adults with obesity. Participants received subcutaneous retatrutide weekly across five dose groups (1mg, 4mg, 8mg, 12mg) or placebo, over 48 weeks. The primary endpoint was percentage change in body weight.<\/p>\n <\/div>\n <\/div>\n \n <div class=\"bp-cl-pullquote\">\n <div class=\"bp-cl-pullquote-stat\">\n 24.2%\n <em>mean body weight reduction \u00b7 12mg dose \u00b7 48 weeks<\/em>\n <\/div>\n <p class=\"bp-cl-pullquote-headline\">The largest body weight reduction ever recorded in a Phase 2 obesity trial \u2014 with 83% of high-dose participants achieving \u226515% reduction and 26% achieving \u226530%.<\/p>\n <p class=\"bp-cl-pullquote-citation\">Source \u2014 New England Journal of Medicine, June 2023<\/p>\n <\/div>\n \n <div class=\"bp-cl-dose-table\">\n <div class=\"bp-cl-dose-table-header\">\n <h3 class=\"bp-cl-dose-table-title\">Dose-Response \u2014 48-Week Endpoint<\/h3>\n <span class=\"bp-cl-dose-table-meta\">Phase 2 \u00b7 n=338 \u00b7 Jastreboff et al., NEJM 2023<\/span>\n <\/div>\n <div class=\"bp-cl-dose-grid\">\n \n <div class=\"bp-cl-dose-row is-header\">\n <div>Dose Group<\/div>\n <div>Mean Weight \u0394<\/div>\n <div>\u22655% Loss<\/div>\n <div>\u226515% Loss<\/div>\n <div>\u226525% Loss<\/div>\n <\/div>\n \n <div class=\"bp-cl-dose-row\">\n <div><span class=\"num\">Placebo<\/span><\/div>\n <div><span class=\"num\">\u22122.1%<\/span><\/div>\n <div><span class=\"num\">27%<\/span><\/div>\n <div><span class=\"num\">2%<\/span><\/div>\n <div><span class=\"num\">0%<\/span><\/div>\n <\/div>\n \n <div class=\"bp-cl-dose-row\">\n <div><span class=\"num\">1mg<\/span><\/div>\n <div><span class=\"num\">\u22127.2%<\/span><\/div>\n <div><span class=\"num\">63%<\/span><\/div>\n <div><span class=\"num\">12%<\/span><\/div>\n <div><span class=\"num\">0%<\/span><\/div>\n <\/div>\n \n <div class=\"bp-cl-dose-row\">\n <div><span class=\"num\">4mg<\/span><\/div>\n <div><span class=\"num\">\u221212.9%<\/span><\/div>\n <div><span class=\"num\">88%<\/span><\/div>\n <div><span class=\"num\">38%<\/span><\/div>\n <div><span class=\"num\">9%<\/span><\/div>\n <\/div>\n \n <div class=\"bp-cl-dose-row\">\n <div><span class=\"num\">8mg<\/span><\/div>\n <div><span class=\"num\">\u221217.3%<\/span><\/div>\n <div><span class=\"num\">93%<\/span><\/div>\n <div><span class=\"num\">63%<\/span><\/div>\n <div><span class=\"num\">24%<\/span><\/div>\n <\/div>\n \n <div class=\"bp-cl-dose-row is-highlight\">\n <div><span class=\"num\">12mg<\/span><span class=\"sub\">Highest dose<\/span><\/div>\n <div><span class=\"num\">\u221224.2%<\/span><span class=\"sub\">vs \u22122.1% placebo<\/span><\/div>\n <div><span class=\"num\">100%<\/span><\/div>\n <div><span class=\"num\">83%<\/span><\/div>\n <div><span class=\"num\">48%<\/span><\/div>\n <\/div>\n \n <\/div>\n <\/div>\n \n <\/div>\n <\/section>\n\n\n <!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n COMPARISON\n \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n <section class=\"bp-cl-compare\">\n <div class=\"bp-cl-compare-inner\">\n \n <div class=\"bp-cl-compare-header\">\n <div class=\"bp-cl-eyebrow\" style=\"justify-content: center;\">Comparative Pharmacology<\/div>\n <h2>Three generations of <em>incretin therapy.<\/em><\/h2>\n <p>Retatrutide sits at the leading edge of a fifteen-year arc in metabolic peptide research. Each generation added receptor coverage. Each generation produced a stronger weight-loss signal in published trials.<\/p>\n <\/div>\n \n <div class=\"bp-cl-compare-grid\">\n \n <div class=\"bp-cl-compare-col\">\n <span class=\"bp-cl-compare-tier\">Generation I<\/span>\n <h3 class=\"bp-cl-compare-name\">Semaglutide<\/h3>\n <span class=\"bp-cl-compare-receptor\">GLP-1 only<\/span>\n \n <div class=\"bp-cl-compare-detail\">\n <span class=\"bp-cl-compare-detail-label\">Peak Weight Loss<\/span>\n <span class=\"bp-cl-compare-detail-value\">\n <span class=\"em-num\">14.9%<\/span>\n STEP 1 trial \u00b7 68 weeks\n <\/span>\n <\/div>\n <div class=\"bp-cl-compare-detail\">\n <span class=\"bp-cl-compare-detail-label\">Receptor Coverage<\/span>\n <span class=\"bp-cl-compare-detail-value\">Single \u2014 GLP-1<\/span>\n <\/div>\n <div class=\"bp-cl-compare-detail\">\n <span class=\"bp-cl-compare-detail-label\">FDA Status<\/span>\n <span class=\"bp-cl-compare-detail-value\">Approved (Wegovy, 2021)<\/span>\n <\/div>\n <div class=\"bp-cl-compare-detail\">\n <span class=\"bp-cl-compare-detail-label\">First Published<\/span>\n <span class=\"bp-cl-compare-detail-value\">Wilding et al., NEJM 2021<\/span>\n <\/div>\n <\/div>\n \n <div class=\"bp-cl-compare-col\">\n <span class=\"bp-cl-compare-tier\">Generation II<\/span>\n <h3 class=\"bp-cl-compare-name\">Tirzepatide<\/h3>\n <span class=\"bp-cl-compare-receptor\">GLP-1 + GIP<\/span>\n \n <div class=\"bp-cl-compare-detail\">\n <span class=\"bp-cl-compare-detail-label\">Peak Weight Loss<\/span>\n <span class=\"bp-cl-compare-detail-value\">\n <span class=\"em-num\">22.5%<\/span>\n SURMOUNT-1 trial \u00b7 72 weeks\n <\/span>\n <\/div>\n <div class=\"bp-cl-compare-detail\">\n <span class=\"bp-cl-compare-detail-label\">Receptor Coverage<\/span>\n <span class=\"bp-cl-compare-detail-value\">Dual \u2014 GLP-1, GIP<\/span>\n <\/div>\n <div class=\"bp-cl-compare-detail\">\n <span class=\"bp-cl-compare-detail-label\">FDA Status<\/span>\n <span class=\"bp-cl-compare-detail-value\">Approved (Zepbound, 2023)<\/span>\n <\/div>\n <div class=\"bp-cl-compare-detail\">\n <span class=\"bp-cl-compare-detail-label\">First Published<\/span>\n <span class=\"bp-cl-compare-detail-value\">Jastreboff et al., NEJM 2022<\/span>\n <\/div>\n <\/div>\n \n <div class=\"bp-cl-compare-col is-featured\">\n <span class=\"bp-cl-compare-tier\">Generation III<\/span>\n <h3 class=\"bp-cl-compare-name\">Retatrutide<\/h3>\n <span class=\"bp-cl-compare-receptor\">GLP-1 + GIP + GCGR<\/span>\n \n <div class=\"bp-cl-compare-detail\">\n <span class=\"bp-cl-compare-detail-label\">Peak Weight Loss<\/span>\n <span class=\"bp-cl-compare-detail-value\">\n <span class=\"em-num\">24.2%<\/span>\n Phase 2 \u00b7 48 weeks (highest dose)\n <\/span>\n <\/div>\n <div class=\"bp-cl-compare-detail\">\n <span class=\"bp-cl-compare-detail-label\">Receptor Coverage<\/span>\n <span class=\"bp-cl-compare-detail-value\">Triple \u2014 GLP-1, GIP, GCGR<\/span>\n <\/div>\n <div class=\"bp-cl-compare-detail\">\n <span class=\"bp-cl-compare-detail-label\">FDA Status<\/span>\n <span class=\"bp-cl-compare-detail-value\">Phase 3 (TRIUMPH program)<\/span>\n <\/div>\n <div class=\"bp-cl-compare-detail\">\n <span class=\"bp-cl-compare-detail-label\">First Published<\/span>\n <span class=\"bp-cl-compare-detail-value\">Jastreboff et al., NEJM 2023<\/span>\n <\/div>\n <\/div>\n \n <\/div>\n \n <\/div>\n <\/section>\n\n\n <!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n LITERATURE\n \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n <section class=\"bp-cl-lit\">\n <div class=\"bp-cl-lit-inner\">\n \n <div class=\"bp-cl-eyebrow\">Selected Literature<\/div>\n \n <h2>The published <em>research footprint.<\/em><\/h2>\n \n <p class=\"bp-cl-lit-intro\">Retatrutide entered the published literature in 2022 and has rapidly become one of the most actively studied metabolic peptides in current clinical research. The selected publications below establish the foundational pharmacology and clinical signal cited throughout this entry.<\/p>\n \n <div class=\"bp-cl-citation\">\n <span class=\"bp-cl-citation-num\">i.<\/span>\n <div class=\"bp-cl-citation-content\">\n <span class=\"bp-cl-citation-meta\">Phase 2 \u2014 Obesity Endpoint<\/span>\n <p class=\"bp-cl-citation-title\">Triple-Hormone-Receptor Agonist Retatrutide for Obesity \u2014 A Phase 2 Trial<\/p>\n <p class=\"bp-cl-citation-authors\">Jastreboff AM, Kaplan LM, Fr\u00edas JP, et al.<\/p>\n <p class=\"bp-cl-citation-journal\"><strong>New England Journal of Medicine<\/strong> \u00b7 2023; 389(6):514\u2013526 \u00b7 DOI: 10.1056\/NEJMoa2301972<\/p>\n <\/div>\n <\/div>\n \n <div class=\"bp-cl-citation\">\n <span class=\"bp-cl-citation-num\">ii.<\/span>\n <div class=\"bp-cl-citation-content\">\n <span class=\"bp-cl-citation-meta\">Phase 2 \u2014 NAFLD Sub-Study<\/span>\n <p class=\"bp-cl-citation-title\">Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease<\/p>\n <p class=\"bp-cl-citation-authors\">Sanyal AJ, Bedossa P, Fraessdorf M, et al.<\/p>\n <p class=\"bp-cl-citation-journal\"><strong>Nature Medicine<\/strong> \u00b7 2024; 30:2071\u20132080 \u00b7 81.4% mean liver fat reduction at 24 weeks<\/p>\n <\/div>\n <\/div>\n \n <div class=\"bp-cl-citation\">\n <span class=\"bp-cl-citation-num\">iii.<\/span>\n <div class=\"bp-cl-citation-content\">\n <span class=\"bp-cl-citation-meta\">Phase 1 \u2014 Type 2 Diabetes<\/span>\n <p class=\"bp-cl-citation-title\">A Single-Ascending-Dose Phase 1 Study of LY3437943, a Novel Triple GIP\/GLP-1\/Glucagon Receptor Agonist<\/p>\n <p class=\"bp-cl-citation-authors\">Coskun T, Urva S, Roell WC, et al.<\/p>\n <p class=\"bp-cl-citation-journal\"><strong>Cell Metabolism<\/strong> \u00b7 2022; 34(9):1234\u20131247 \u00b7 Foundational PK\/PD characterisation<\/p>\n <\/div>\n <\/div>\n \n <div class=\"bp-cl-citation\">\n <span class=\"bp-cl-citation-num\">iv.<\/span>\n <div class=\"bp-cl-citation-content\">\n <span class=\"bp-cl-citation-meta\">Phase 2 \u2014 Type 2 Diabetes Endpoint<\/span>\n <p class=\"bp-cl-citation-title\">Retatrutide for the Treatment of Type 2 Diabetes \u2014 Phase 2 Trial<\/p>\n <p class=\"bp-cl-citation-authors\">Rosenstock J, Fr\u00edas JP, Jastreboff AM, et al.<\/p>\n <p class=\"bp-cl-citation-journal\"><strong>The Lancet<\/strong> \u00b7 2023; 402(10401):529\u2013544 \u00b7 Glycaemic and weight-loss endpoints in T2D population<\/p>\n <\/div>\n <\/div>\n \n <div class=\"bp-cl-citation\">\n <span class=\"bp-cl-citation-num\">v.<\/span>\n <div class=\"bp-cl-citation-content\">\n <span class=\"bp-cl-citation-meta\">Phase 3 \u2014 TRIUMPH Programme<\/span>\n <p class=\"bp-cl-citation-title\">TRIUMPH-1 through TRIUMPH-5 \u2014 Phase 3 Clinical Programme<\/p>\n <p class=\"bp-cl-citation-authors\">Eli Lilly &amp; Company<\/p>\n <p class=\"bp-cl-citation-journal\"><strong>ClinicalTrials.gov<\/strong> \u00b7 NCT05929066, NCT05882045, NCT05882110, NCT05536804, NCT05882045 \u00b7 Ongoing trials with anticipated readouts 2026\u20132027<\/p>\n <\/div>\n <\/div>\n \n <\/div>\n <\/section>\n\n\n <!-- \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\n BUY MOMENT\n \u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550\u2550 -->\n <section class=\"bp-cl-buy\">\n <div class=\"bp-cl-buy-inner\">\n \n <div class=\"bp-cl-buy-content\">\n \n <div class=\"bp-cl-buy-eyebrow\">Available from Bangkok Peptides<\/div>\n \n <h2>Retatrutide, supplied <em>locally<\/em> in Thailand.<\/h2>\n \n <p class=\"bp-cl-buy-lede\">Bangkok Peptides supplies retatrutide as a research-grade peptide for laboratory use only. \u226599% HPLC\/MS verified purity. Third-party tested by Janoshik at the manufacturing stage, with independent batch reports published per batch. Same-day Bangkok dispatch with tracked nationwide delivery across <a href=\"\/retatrutide-thailand\/\">Thailand<\/a>. New to the compound? Read <a href=\"\/what-is-retatrutide\/\">what retatrutide is<\/a> and how it works.<\/p>\n \n <div class=\"bp-cl-buy-specs\">\n <div class=\"bp-cl-buy-spec\">\n <span class=\"bp-cl-buy-spec-label\">Vial Strengths<\/span>\n <span class=\"bp-cl-buy-spec-value\">10 \/ 20 \/ 30mg<\/span>\n <\/div>\n <div class=\"bp-cl-buy-spec\">\n <span class=\"bp-cl-buy-spec-label\">Purity<\/span>\n <span class=\"bp-cl-buy-spec-value\">\u226599% HPLC\/MS<\/span>\n <\/div>\n <div class=\"bp-cl-buy-spec\">\n <span class=\"bp-cl-buy-spec-label\">Dispatch<\/span>\n <span class=\"bp-cl-buy-spec-value\">Same-Day Bangkok<\/span>\n <\/div>\n <\/div>\n \n <div class=\"bp-cl-buy-cta-row\">\n <a href=\"\/product\/retatrutide\/\" class=\"bp-cl-buy-cta\">\n Buy Retatrutide\n <span>\u2192<\/span>\n <\/a>\n <a href=\"\/retatrutide-vs-tirzepatide-vs-semaglutide\/\" class=\"bp-cl-buy-cta-secondary\">\n See Comparison\n <\/a>\n <\/div>\n \n <p class=\"bp-cl-buy-price\">\n <strong>From \u0e3f3,800<\/strong> \u00b7 10mg \/ 20mg \/ 30mg vial \u00b7 For research use only\n <\/p>\n \n <\/div>\n \n <div class=\"bp-cl-buy-visual\">\n <img decoding=\"async\" src=\"https:\/\/bangkokpeptides.com\/wp-content\/uploads\/2026\/04\/Retatrutide-10mg-m.jpg\" alt=\"Bangkok Peptides Retatrutide vial \u2014 research peptide Thailand\">\n <\/div>\n \n <\/div>\n <\/section>\n\n<\/div>\n\n\n\n<script type=\"application\/ld+json\">\n{\n \"@context\": \"https:\/\/schema.org\",\n \"@type\": \"TechArticle\",\n \"@id\": \"https:\/\/bangkokpeptides.com\/compound-library-retatrutide\/#article\",\n \"headline\": \"Retatrutide \u2014 Compound Library Volume I\",\n \"alternativeHeadline\": \"Triple-Receptor Agonist (GLP-1 + GIP + GCGR)\",\n \"description\": \"Comprehensive editorial reference for retatrutide \u2014 the first triple-receptor agonist peptide engaging GLP-1, GIP, and glucagon pathways simultaneously. Covers mechanism, Phase 2 trial data (24.2% mean weight reduction, NEJM 2023), comparative pharmacology against semaglutide and tirzepatide, and selected literature.\",\n \"author\": {\n \"@type\": \"Organization\",\n \"@id\": \"https:\/\/bangkokpeptides.com\/#organization\",\n \"name\": \"Bangkok Peptides\"\n },\n \"publisher\": {\n \"@type\": \"Organization\",\n \"@id\": \"https:\/\/bangkokpeptides.com\/#organization\",\n \"name\": \"Bangkok Peptides\",\n \"logo\": {\n \"@type\": \"ImageObject\",\n \"url\": \"https:\/\/bangkokpeptides.com\/wp-content\/uploads\/2026\/01\/BANGKOK-Header-Logo-New-Gold.png\"\n }\n },\n \"datePublished\": \"2026-04-30\",\n \"dateModified\": \"2026-04-30\",\n \"image\": \"https:\/\/bangkokpeptides.com\/wp-content\/uploads\/2026\/04\/Retatrutide-10mg-m.jpg\",\n \"mainEntityOfPage\": \"https:\/\/bangkokpeptides.com\/compound-library-retatrutide\/\",\n \"keywords\": \"retatrutide, triple agonist, GLP-1, GIP, glucagon, LY3437943, metabolic peptide, NEJM 2023, Phase 2, Phase 3, TRIUMPH, Eli Lilly, weight loss research\",\n \"about\": [\n {\n \"@type\": \"ChemicalSubstance\",\n \"name\": \"Retatrutide\",\n \"alternateName\": [\"LY3437943\", \"Triple Agonist\"],\n \"mechanismOfAction\": \"Triple-receptor agonist \u2014 simultaneous activation of GLP-1, GIP, and glucagon (GCGR) receptors\",\n \"clinicalPharmacology\": \"Phase 2 trial (Jastreboff et al., NEJM 2023): 24.2% mean body weight reduction at 12mg dose over 48 weeks. 83% of high-dose participants achieved \u226515% weight loss. Sub-study in NAFLD (Sanyal et al., Nature Medicine 2024): 81.4% mean liver fat reduction at 24 weeks.\",\n \"code\": {\n \"@type\": \"MedicalCode\",\n \"code\": \"2381089-83-2\",\n \"codingSystem\": \"CAS\"\n }\n }\n ],\n \"citation\": [\n {\n \"@type\": \"ScholarlyArticle\",\n \"headline\": \"Triple-Hormone-Receptor Agonist Retatrutide for Obesity \u2014 A Phase 2 Trial\",\n \"author\": \"Jastreboff AM, Kaplan LM, Fr\u00edas JP, et al.\",\n \"datePublished\": \"2023\",\n \"publisher\": {\n \"@type\": \"Organization\",\n \"name\": \"New England Journal of Medicine\"\n },\n \"identifier\": \"10.1056\/NEJMoa2301972\"\n },\n {\n \"@type\": \"ScholarlyArticle\",\n \"headline\": \"Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease\",\n \"author\": \"Sanyal AJ, Bedossa P, Fraessdorf M, et al.\",\n \"datePublished\": \"2024\",\n \"publisher\": {\n \"@type\": \"Organization\",\n \"name\": \"Nature Medicine\"\n }\n },\n {\n \"@type\": \"ScholarlyArticle\",\n \"headline\": \"A Single-Ascending-Dose Phase 1 Study of LY3437943, a Novel Triple GIP\/GLP-1\/Glucagon Receptor Agonist\",\n \"author\": \"Coskun T, Urva S, Roell WC, et al.\",\n \"datePublished\": \"2022\",\n \"publisher\": {\n \"@type\": \"Organization\",\n \"name\": \"Cell Metabolism\"\n }\n },\n {\n \"@type\": \"ScholarlyArticle\",\n \"headline\": \"Retatrutide for the Treatment of Type 2 Diabetes \u2014 Phase 2 Trial\",\n \"author\": \"Rosenstock J, Fr\u00edas JP, Jastreboff AM, et al.\",\n \"datePublished\": \"2023\",\n \"publisher\": {\n \"@type\": \"Organization\",\n \"name\": \"The Lancet\"\n }\n }\n ],\n \"isRelatedTo\": [\n { \"@id\": \"https:\/\/bangkokpeptides.com\/product\/retatrutide\/#bp-product\" },\n { \"@id\": \"https:\/\/bangkokpeptides.com\/retatrutide-thailand\/#article\" },\n { \"@id\": \"https:\/\/bangkokpeptides.com\/what-is-retatrutide\/#article\" },\n { \"@id\": \"https:\/\/bangkokpeptides.com\/retatrutide-vs-tirzepatide-vs-semaglutide\/#article\" }\n ]\n}\n<\/script>\n\n<script type=\"application\/ld+json\">\n{\n \"@context\": \"https:\/\/schema.org\",\n \"@type\": \"BreadcrumbList\",\n \"itemListElement\": [\n {\n \"@type\": \"ListItem\",\n \"position\": 1,\n \"name\": \"Home\",\n \"item\": \"https:\/\/bangkokpeptides.com\/\"\n },\n {\n \"@type\": \"ListItem\",\n \"position\": 2,\n \"name\": \"Compound Library\",\n \"item\": \"https:\/\/bangkokpeptides.com\/library\/\"\n },\n {\n \"@type\": \"ListItem\",\n \"position\": 3,\n \"name\": \"Retatrutide\",\n \"item\": \"https:\/\/bangkokpeptides.com\/compound-library-retatrutide\/\"\n }\n ]\n}\n<\/script>\n","protected":false},"excerpt":{"rendered":"<p>Compound Library Volume I Phase 3 \u2014 TRIUMPH Retatrutide Triple-receptor agonist The first peptide to engage GLP-1, GIP, and glucagon receptors simultaneously \u2014 and the most extensively studied compound in current metabolic research literature. CAS Number 2381089-83-2 Class Triple Agonist GLP-1 \/ GIP \/ GCGR Developer Eli Lilly LY3437943 First Published NEJM 2023 Jastreboff et [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":4793,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-4791","page","type-page","status-publish","hentry"],"blocksy_meta":{"has_hero_section":"disabled","styles_descriptor":{"styles":{"desktop":"","tablet":"","mobile":""},"google_fonts":[],"version":6}},"_links":{"self":[{"href":"https:\/\/bangkokpeptides.com\/th\/wp-json\/wp\/v2\/pages\/4791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bangkokpeptides.com\/th\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/bangkokpeptides.com\/th\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/bangkokpeptides.com\/th\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bangkokpeptides.com\/th\/wp-json\/wp\/v2\/comments?post=4791"}],"version-history":[{"count":5,"href":"https:\/\/bangkokpeptides.com\/th\/wp-json\/wp\/v2\/pages\/4791\/revisions"}],"predecessor-version":[{"id":8459,"href":"https:\/\/bangkokpeptides.com\/th\/wp-json\/wp\/v2\/pages\/4791\/revisions\/8459"}],"up":[{"embeddable":true,"href":"https:\/\/bangkokpeptides.com\/th\/wp-json\/wp\/v2\/pages\/4793"}],"wp:attachment":[{"href":"https:\/\/bangkokpeptides.com\/th\/wp-json\/wp\/v2\/media?parent=4791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}